GBIO Generation Bio

Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a fireside chat at the 2022 Jefferies Cell & Genetic Medicine Summit on Thursday, September 29th at 10:30 a.m. ET in New York.

A live webcast of the presentation will be available on the investor section of the company’s website at . A replay will be available there for 30 days following the event.

About Generation Bio

Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

For more information, please visit . 

Investors and Media Contact

Maren Killackey

Generation Bio



857-371-4638



EN
22/09/2022

Underlying

GBIOGeneration Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Generation Bio

Wedbush Research
  • Wedbush Research
TSLA TESLA INC
GOOGL ALPHABET INC. CLASS A
AMZN AMAZON.COM INC.
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
GBIO GENERATION BIO
DASH DOORDASH
PAY PAYMENTUS HLDGS INC
TYRA TYRA BIOSCIENCES INC
CART MAPLEBEAR INC.
12/16/25 December 16, 2025 1 EN
David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
12/16/25 December 16, 2025 1 EN
 PRESS RELEASE
Free
GBIO GENERATION BIO

XOMA Royalty Enters into Agreement to Acquire Generation Bio

XOMA Royalty Enters into Agreement to Acquire Generation Bio - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) delivery platform for small interfering RNA (siRNA) and other nucleic acid therapies to be included in XOMA Royalty’s portfolio - EMERYVILLE, Calif. and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has entered into an ag...

December 15, 2025 1 EN
 PRESS RELEASE
Free
GBIO GENERATION BIO

Generation Bio Announces Third Quarter 2025 Financial Results

Generation Bio Announces Third Quarter 2025 Financial Results CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: GBIO), a biotechnology company, today reported third quarter financial results. Third Quarter 2025 Financial Results Cash Position: Cash, cash equivalents, and marketable securities were $89.6 million as of September 30, 2025, compared to $185.2 million as of December 31, 2024. The company expects that its cash, cash equivalents, and marketable securities will fund its operating expenditures for the foreseeable future.R&D Expenses: Research and development (R&D) e...

November 5, 2025 1 EN
 PRESS RELEASE
Free
GBIO GENERATION BIO

Generation Bio Announces CEO Transition

Generation Bio Announces CEO Transition • Geoff McDonough, MD to step down as CEO & President and become Chair of the Company’s Board of Directors • Current Chief Legal Officer Yalonda Howze, JD named Interim CEO & President CAMBRIDGE, MASS., Oct. 22, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, today announced that Geoff McDonough, MD will step down as Chief Executive Officer and President, and will Chair the company’s Board of Directors. The Board has appointed Yalonda How...

October 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch